| Company | Date | Position | Consensus β | Price Target β | 2-Yr Return | vs S&P 500 β |
|---|---|---|---|---|---|---|
|
LLY
Eli Lilly & Co
|
Oct 30, 2026 | BUY |
Strong Buy
-16.7% avg upside
50 analysts
|
$1573.00
10.88% Upside
|
+1.1% | Β· |
|
ABBV
AbbVie
|
Oct 30, 2026 | HOLD |
Strong Buy
-14.5% avg upside
47 analysts
|
$294.00
0.30% Downside
|
-0.7% | Β· |
|
JNJ
Johnson & Johnson
|
Oct 26, 2026 | BUY |
Strong Buy
-9.1% avg upside
40 analysts
|
$280.00
2.50% Upside
|
+6.6% | Β· |
|
MRK
Merck & Company
|
Oct 22, 2026 | BUY |
Strong Buy
-3.5% avg upside
44 analysts
|
$155.00
3.69% Upside
|
-2.6% | Β· |
|
JP:4519
Chugai Pharmaceutical Co
|
Oct 20, 2026 | BUY |
Strong Buy
+35.7% avg upside
7 analysts
|
$8750.00
28.20% Upside
|
+13.4% | Β· |
|
BMY
Bristol-Myers Squibb
|
Oct 19, 2026 | HOLD |
Buy
-2.2% avg upside
42 analysts
|
$63.00
0.93% Upside
|
+7.0% | Β· |
|
BNTX
BioNTech SE
|
Oct 13, 2026 | BUY |
Strong Buy
+48.9% avg upside
28 analysts
|
$127.00
43.95% Upside
|
-4.7% | Β· |
|
PCVX
Vaxcyte
|
Oct 06, 2026 | HOLD |
Strong Buy
+77.8% avg upside
15 analysts
|
$85.00
36.94% Upside
|
-10.9% | Β· |
|
RPRX
Royalty Pharma
|
Aug 06, 2026 | BUY |
Strong Buy
-12.2% avg upside
15 analysts
|
$66.00
1.78% Downside
|
+20.8% | Β· |
|
PFE
Pfizer
|
Aug 04, 2026 | HOLD |
Buy
+9.2% avg upside
46 analysts
|
$26.00
14.91% Downside
|
+13.7% | Β· |
|
NAMS
NewAmsterdam Pharma Company
|
May 07, 2026 | HOLD |
Strong Buy
+136.0% avg upside
19 analysts
|
$38.00
89.49% Upside
|
-44.4% | Β· |
|
INVA
Innoviva
|
May 06, 2026 | SELL |
Buy
+37.9% avg upside
13 analysts
|
$18.00
15.11% Downside
|
+18.7% | Β· |
|
XRAY
DENTSPLY SIRONA
|
Dec 16, 2019 | BUY |
Buy
+182.3% avg upside
25 analysts
|
$66.00
592.48% Upside
|
-4.3% | Β· |
|
AMGN
Amgen
|
Dec 16, 2019 | BUY |
Buy
-29.9% avg upside
57 analysts
|
$270.00
42.09% Downside
|
-3.0% | Β· |
|
ICLR
Icon
|
Dec 14, 2018 | BUY |
Strong Buy
-1.8% avg upside
28 analysts
|
$168.00
20.53% Downside
|
+42.9% | Β· |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.